Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study aims to identify the number of MODY patients to be found among Emirati women with GDM as the incidence and prevalence of monogenic diabetes among this group of patients is unknown. This will enable improvements in diagnostics, treatment and the counselling of these women.
The present study aims to perform systematic genetic screening of genes known as the cause of MODY in women diagnosed with gestational diabetes to estimate the prevalence of MODY. This is important to understand the extent to which monogenic diabetes is encountered for the first time during pregnancy. Once women with MODY developing GDM have been identified, biomarkers to identify these women can be found which will assist the clinical process of performing genetic screening in the right subset of patients. Also for the women participating in the present study, this is of great importance as correct genetic diagnosis will provide them with the needed information to receive optimal treatment, correct plan for follow-up and a more accurate prognosis in relation to risk of future complication and therefore prevention of such.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| GDM Current | Currently pregnant women diagnosed with GDM. Next generation sequencing (NGS) methodologies will used on individuals suspected of genetic diabetes. |
| |
| GDM History | Women with history of GDM (with negative GAD/IA2 antibodies if results available). Next generation sequencing (NGS) methodologies will used on individuals suspected of genetic diabetes. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Next generation sequencing (NGS) | Genetic | NGS Panel, Whole exome/genome sequencing |
|
| Measure | Description | Time Frame |
|---|---|---|
| GDM Identification | Identifying individuals with history of GDM or current diagnosis of GDM and analysing their GTT results and likelihood of MODY. GTT results will be extracted from patient's medical records. | through study completion, an average of 2 year |
| Measure | Description | Time Frame |
|---|---|---|
| Next Generation Sequencing (NGS) | Next Generation Sequencing (NGS) technology will be applied to perform genetic testing, analysing 13 previously published MODY genes and potentially identifying novel causative mutations. | through study completion, an average of 2 year |
| Novel diabetes genes |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Pregnant women diagnosed with GDM, through Imperial College London Diabetes Centre (ICLDC) gestational diabetes clinic.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Hinda Daggag, PhD | Contact | +971 2 404 0800 | hdaggag@icldc.ae |
| Name | Affiliation | Role |
|---|---|---|
| Maha Barakat, PhD FRCP | Imperial College London Diabetes Centre | Principal Investigator |
| Torben Hansen, MD PhD | University of Copenhagen | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Imperial College London Diabetes Centre | Recruiting | Abu Dhabi | 48338 | United Arab Emirates |
Not provided
| ID | Term |
|---|---|
| D016640 | Diabetes, Gestational |
| C562772 | Mason-Type Diabetes |
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D011248 | Pregnancy Complications |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D003920 | Diabetes Mellitus |
Not provided
Not provided
| ID | Term |
|---|---|
| D059014 | High-Throughput Nucleotide Sequencing |
| ID | Term |
|---|---|
| D017421 | Sequence Analysis |
| D005821 | Genetic Techniques |
| D008919 | Investigative Techniques |
Not provided
Not provided
Not provided
Not provided
Not provided
DNA will be extracted from collected blood samples for genetic analysis
Identifying novel diabetes genes in the Emirati women with GDM by performing whole exome sequencing. |
| through study completion, an average of 2 year |
| Genetic test results validation | Validating positive genetic test results by performing mutational analysis on parental, siblings and relatives samples. Request from parents, siblings and/or relatives to participate in the study will only occur if a novel (potentially pathogenic mutation) is identified and the primary participant agrees to it. | through study completion, an average of 2 year |
| Potential biomarkers | Identifying potential biomarkers in women with MODY and who are developing GDM, to assist the selection of women suitable for genetic screening. | through study completion, an average of 2 year |
| Prevalence of MODY | Determining the prevalence of MODY in women with GDM in the UAE. | through study completion, an average of 2 year |
| Clinical outcomes determination | Determining the short and the long-term clinical outcomes of MODY in women with GDM in the UAE | through study completion, an average of 2 year |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |